Great AGM - forecast 50% rev growth in 2020. Still no...

Great AGM - forecast 50% rev growth in 2020. Still no competition (with FDA, CE, cFDA) approvals - our tech is still gold std for cBP. Blumio and Mobvoi progressing well (and large marketshare fight by large tech companies to own this space - Amazon, Google, Apple, etc). Inhealth progressing well. Physician reimbursement from CPT @ ~US$20 per test, however, total reimbursement based on health outcomes closer to $US190 - where health outcomes (lower BP and medication, etc) - will drive future growth.

Directors have large holding and therefore driving CDX for all s/holders and self-interest - which works for me (as self-interest is the best motivator).

GLTAH.